Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ebastine plus docetaxel for castration-resistant metastatic prostate cancer
2019-004259-35Phase 2Active
- Sponsor
- Rigshospitalet
- Start
- Jun 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in castration-resistant prostate cancer (CRPC) comparing Docetaxel + ebastine with Docetaxel alone (2 arms). Primary endpoint: Change in urine biomarkers (BMP). Started Jun 2020; status: active.
02
Drugs
eribulindocetaxel
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2019-004259-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004259-35.